BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2026 7:28:51 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-09-16 03:43 |
|
Peer-Review Started |
|
2025-09-16 03:43 |
|
First Decision by Editorial Office Director |
|
2025-09-25 07:38 |
|
Return for Revision |
|
2025-09-25 07:38 |
|
Revised |
|
2025-11-23 17:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-26 02:58 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-26 09:17 |
|
Articles in Press |
|
2026-01-26 09:17 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-26 00:22 |
|
Publish the Manuscript Online |
|
2026-04-08 07:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Basic Study |
| Article Title |
HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jin-Hui Huang and Jin-Qi Ma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jin-Qi Ma, Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, Hunan Province, China. 601237@csu.edu.cn |
| Key Words |
Colorectal cancer; Synthetic lethal; Atorvastatin; Gefitinib; Autophagy |
| Core Tip |
Integrated analysis of data from the SOLAD, CSSL, and SynLethDB databases was performed to identify HMGCR as a PIK3CD-interacting synthetic lethal partner. Atorvastatin in combination with gefitinib synergistically inhibited the proliferation and metastasis of colorectal cancer (CRC) cells through a synthetic lethal effect via the AMP-activated protein kinase–sterol regulatory element-binding protein 1 signaling pathway. This study provides new research ideas for CRC treatment. |
| Publish Date |
2026-04-08 07:28 |
| Citation |
Huang JH, Ma JQ. HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells. World J Gastrointest Oncol 2026; 18(4): 114220 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i4/114220.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i4.114220 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
